Kornimate/medical-research-clean huggingface dataset:
effectiveness and mechanisms of recovery oriented cognitive therapy

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this study is evaluating the effectiveness of recovery oriented cognitive therapy (ct-r) for patients with schizophrenia/schizoaffective disorder. to evaluate ct-r, the investigators are conducting a randomized controlled trial with patients from community mental health centers. participants will be randomized to the ct-r condition, in which the participants will receive approximately 9 months of ct-r as an adjunctive treatment to current medical treatment, or to the continued usual care control condition. the primary outcome measure (positive, negative, and general psychopathology symptoms) as well as secondary measures (quality of life, self-esteem, social anhedonia, recovery, dysfunctional attitudes, resilience, internalized stigma, and hopelessness) will be measured at baseline, 4-5 months after the first therapy appointment, approximately 9 months after the first therapy appointment, and approximately 15 months after the baseline appointment.

background/purpose: despite effective medical treatment, many patients with psychotic illnesses experience poor long-term functional outcomes possibly due to certain psychosocial factors that can interfere with recovery. ct-r was developed to address these factors by leading the individual to substantive progress by addressing any obstacles and promoting a cognitive shift in their beliefs in their own personal and social efficacy. the goal of this study is to evaluate the effectiveness and mechanisms of ct-r as an adjunctive treatment for individuals with schizophrenia/schizoaffective disorder. population: participants will include individuals currently receiving pharmacological treatment for schizophrenia or schizoaffective disorder. therapist participants who have preliminary training in ct-r will be recruited as well to deliver the treatment. therapists will first complete a training phase consisting of a workshop and approximately 3 months of group supervision while providing ct-r to 1 training case each. intervention: the ct-r that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. in ct-r, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.

Eligibility criteria:
inclusion criteria: * patients: between 18 and 65 years old with a diagnosis of schizophrenia or schizoaffective disorder, proficient in english, currently under the care of a physician and on medication for schizophrenia/schizoaffective disorder, and able to provide informed consent. * therapists: 25 years of age or above, licensed therapist, preliminarily trained in ct-r. exclusion criteria: * patients: medical comorbidities causing brain damage (e.g., stroke, dementia), significant suicidal risk/ideation requiring immediate referral or suicidal gesture.
effect of dilatation and curettage on the endometrial receptivity

Conditions: Embryo Implantation

Summary: effect of dilatation and curettage on the endometrial receptivity and pregnancy outcome in patients with recurrent implantation failure


Eligibility criteria:
inclusion criteria: 1. all the patients had at least 3 failed trials of ivf-et with day 5 fresh blastocyst transferred 2. at least 10 high-grade embryos were obtained in the previous trials 3. level of amh more than or equal 1.1 ng/ml. 4. age: less than or equal to 35 years exclusion criteria: 1. patients with uterine pathology e.g. myoma , asherman syndrome, septum ,adenomyosis 2. hydrosalpinx 3. endometriosis 4. patients with diagnosed autoimmune diseases affecting pregnancy e.g. s.l.e.
incidence, risk factors, and risk model of acute kidney injury in pediatric patients who undergoing surgery for congenital heart disease

Conditions: Patients Undergoing Surgery for Congenital Heart Disease

Summary: acute kidney injury (aki) is a major complication after cardiac surgery and has been reported to be associated with adverse outcome. previous studies have reported that the incidence of aki in patients undergoing surgery for congenital heart disease is as high as 42% and aki increase the patient mortality, intensive care unit stay and hospital stay. previous studies have reported several risk factors for aki after congenital heart surgery, however, perioperative variables including anesthesia-related factors have not been evaluated fully. therefore, the investigators attempt to find out independent risk factors regarding perioperative variables.

acute kidney injury (aki) is a major complication after cardiac surgery and has been reported to be associated with adverse outcome. previous studies have reported that the incidence of aki in patients undergoing surgery for congenital heart disease is as high as 42% and aki increase the patient mortality, intensive care unit stay and hospital stay. previous studies have reported several risk factors for aki after congenital heart surgery, however, perioperative variables including anesthesia-related factors have not been evaluated fully. in addition, a neutrophil-lymphocyte ratio (nlr), which have been reported to be a marker for systemic inflammation and associated with prognosis of cardiac and cancer patients might be able to predict development of postoperative aki. therefore, the investigators attempt to assess independent risk factors regarding perioperative variables including transfusion-related parameters, preoperative anemia, preoperative hypoalbuminemia, pulmonary hypertension, use of nitric oxide, use of hydroxyethyl starch, perioperative medication, hemodynamic variables and perioperative nlr.

Eligibility criteria:
inclusion criteria: * patients who underwent surgery for congenital heart disease between january 2012 and december 2012 in samsung medical center exclusion criteria: * incomplete data for creatinine, estimated glomerular filtration rate, or urine output required to diagnose acute kidney injury * patients who expired within 24 hours after surgery

Keywords: congenital heart disease acute kidney injury risk factor anesthesia
tolerance and efficacy of a predigested, high protein, high omega 3 fat enteral feeding formula versus a standard formula in multiple intensive care unit settings

Conditions: Critical Illness; Enteral Feeding

Summary: the purpose of this pilot study is to assess the efficacy, safety and tolerance profile of the enteral feeding product vital af (a semi-elemental, high protein, and high omega-3 fish oil) when compared to osmolite 1.2, a standard feeding product in critically ill and/or post surgical patients in the intensive care unit (icu). if enough patients are recruited, inferences about impact on outcomes may also be drawn.


Eligibility criteria:
inclusion criteria: * subject requires enteral tube feeding as sole source of nourishment * subject, or subject's legally acceptable representative (lar), has provided voluntarily and informed consent form, as deemed appropriate and approved by the columbia university medical center institutional review board * subject is ≥ 18 years of age * subject is male or non-pregnant female at least six weeks postpartum and non-lactating females of childbearing potential will be required to confirm non-pregnancy status with a pregnancy test at screening * subject has an initial apache ii score less than or equal to 24 exclusion criteria: * subject requires parenteral nutrition * subject is acutely impacted or constipated * subject has intestinal obstruction * subject is too hemodynamically unstable for enteral feeding * subject has an allergy or intolerance to any ingredient in the study product by documentation or verbal report by subject or subject's lar * subject is participating in a non-abbott approved concomitant trial * subject has gastrointestinal disease, including acute pancreatitis, active gastrointestinal bleeding, acute inflammatory bowel disease, or has undergone intestinal surgery within the past month
growth factor signature (gfs) pilot study (mk0000-098)(completed)

Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML); Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)

Summary: this study will evaluate a gene expression signature (growth factor signature \[gfs\]) as a biomarker for response/resistance to brc-abl oncogene inhibitors.


Eligibility criteria:
inclusion criteria: * participant must have a histologically or cytopathologically confirmed blast phase ph+ cml or ph+ all. * participant is 18 years of age on the day of signing informed consent * participant must have performance status 0-3 on the eastern cooperative oncology group (ecog) performance scale * participant has at least 30 percent blasts in peripheral blood; or at least 30 percent lymphoblasts in peripheral blood or bone marrow * for part ii: * participant has progressed while taking imatinib or is unable to tolerate imatinib, being defined as discontinuing imatinib treatment as a result of nonhematologic toxic effects of any grade * if female, participant is either post-menopausal, free from menses for \>2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the study, starting with visit 1 * female participants of childbearing potential must have a negative serum or urine pregnancy test (beta hcg) at screening * if male, participant is surgically sterilized, agrees to use an adequate method of contraception, or agrees to abstain from heterosexual activity for the duration of the study * participant or the patrticipant's legal representative has voluntarily agreed to participate by giving written informed consent * participant must be available for periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study exclusion criteria: * participant is currently participating in or has participated in a study with an investigational compound or device within 30 days or 5 half-lives, whichever is longer, of the start of treatment * participant has known human immunodeficiency virus (hiv) infection or hiv-related malignancy * participant is a female who is pregnant or breastfeeding, or is expecting to conceive within the projected duration of the study * participant has a known allergy or hypersensitivity to imatinib, dasatinib or nilotinib * participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate * participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * there is any concern by the investigator regarding the safe participation of the participant in the study or for any other reason, the investigator considers the participant inappropriate for participation in the study
facemasks and chronic pain patients with hearing loss

Conditions: Hearing Loss; Chronic Pain

Summary: facemasks may impede communication. impaired communication may worsen healthcare outcomes. this study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. data collection includes patient's age, anxiety score, depression score, numeric pain score, and effects of facemasks on treatment outcomes. pain is measured using numeric pain rating scale. depression is measured using the patient health questionnaire (phq-9) scale. anxiety is measured using the general anxiety disorder (gad-7) scale.

facemasks may impede communication. impaired communication may worsen healthcare outcomes. there is inadequate data on the prevalence of hearing impairment in chronic pain patients. there is inadequate information about the impact of facemasks on treatment outcomes in chronic pain patients with hearing impairment. this prospective study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. this is a prospective cohort study of adult patients undergoing pain treatment at an interventional pain clinic in canada. data collection includes patient's age, anxiety score, depression score, analgesic usage, numeric pain score, and effects of facemasks on pain management outcomes. pain is measured using numeric pain rating scale of 0-10, with change of 2-points being considered significant. depression is measured using the patient health questionnaire (phq-9) scale of 0-27, with change of 3-points being considered significant. anxiety is measured using the general anxiety disorder (gad-7) scale of 0-21, with change of 3-points being considered significant. data are analyzed with ibm® spss® statistics 25; using student's t-test, anova, pearson chi-square test, and regression analysis. p-value \<0.05 is considered significant.

Eligibility criteria:
inclusion criteria: * adults * chronic pain diagnosis * diagnosed hearing impairment * use of hearing aid exclusion criteria: * complete deafness * cochlear implant * severe vision impairment * cognitive dysfunction
comparison of postoperative analgesic efficacy of transversus abdominis plane block (tap) and modified thoracoabdominal nerve block (m-tapa)

Conditions: Laparoskopic Cholecystectomy; Transversus Abdominis Plane (TAP) Block; Modified Thoracoabdominal Nerve Block (M-TAPA)

Summary: laparoscopic cholecystectomy is a frequently performed surgical procedure and is considered the gold standard for treating symptomatic gallstone disease. although laparoscopic cholecystectomy is considered minimally invasive, it can cause moderate to severe pain in the postoperative period. poorly controlled early postoperative pain can impair recovery quality and increase the risk of postoperative pulmonary complications as a risk factor for chronic pain development. multimodal analgesia, including opioids, is used to limit pain following laparoscopic cholecystectomy. however, opioid treatment may lead to side effects such as postoperative nausea and vomiting (ponv), respiratory depression, and constipation. nerve blocks provide better pain control, reduce opioid consumption in the postoperative period, and offer advantages such as fewer side effects and a lower risk of pulmonary and cardiac complications. in our clinic, a multimodal analgesia approach is preferred for patients undergoing laparoscopic cholecystectomy. in addition to intravenous analgesic agents, peripheral nerve blocks are administered based on patient preference (for all eligible and consenting patients). this study aims to compare the postoperative analgesic efficacy of the transversus abdominis plane (tap) block and the modified thoracoabdominal nerve block with a pericostal approach (m-tapa) in patients undergoing laparoscopic cholecystectomy. standard analgesic methods are applied to patients who do not consent to peripheral nerve block administration.


Eligibility criteria:
inclusion criteria: * 18 to 65 years old * american society of anesthesiologists (asa) physical status i-ii-iii * body mass index 18 to 30 kg/m2 * elective laparoscopic cholecystectomy surgery exclusion criteria: * under 18 and over 65 * asa score iv and above * advanced co-morbidity * history of bleeding diathesis * patient refusing the procedure * chronic opioid or analgesic use * patients who will operate under emergency conditions * block injection site infection * known allergy to local anesthetics * pregnancy

Keywords: remifantanile conception acute pain postoperatif pain
study of the silverhawk™ /turbohawk™ plaque excision systems used with spiderfx to treat calcified peripheral arterial disease (definitive ca++)

Conditions: Peripheral Arterial Disease

Summary: this is a multi-center, non-randomized, single arm study of the silverhawk™ /turbohawk™ plaque excision systems when used in conjunction with spiderfx™ embolic protection device in treatment of moderate to severely calcified peripheral arterial disease in the superficial femoral and/or popliteal arteries.


Eligibility criteria:
inclusion criteria: * provides written informed consent * willing to comply with follow-up evaluations at specified times * has leg pain due to peripheral arterial disease * disease located within the femoropopliteal artery * moderate to severe calcification exclusion criteria: * previously implanted stent(s) or stent graft(s) in target leg * life expectancy less than 12 months * has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure

Keywords: peripheral vascular disease atherectomy atherosclerosis calcified lesions
efficacy and safety of ibi-10090 in ocular surgery patients

Conditions: Inflammation Associated With Cataract Surgery

Summary: this study will test the efficacy and safety of ibi-10090 in the treatment of ocular inflammation after ocular surgery.


Eligibility criteria:
inclusion criteria: * patients scheduled for unilateral cataract surgery exclusion criteria: * ocular, topical, or oral corticosteroids within 7 days of day 0

Keywords: cataract surgery ocular inflammation
wake up symptomatic stroke - benefit of intravenous clot busters or endovascular intervention

Conditions: Stroke

Summary: the purpose of the trial is to study the safety and the effectiveness of using ct perfusion studies as an indicator to treat stroke patients with unknown time of onset.


Eligibility criteria:
inclusion criteria: inclusion criteria: to be eligible for entry into this study, candidates must meet all of the following eligibility criteria at the time of emergency department presentation: 1. age: 18-80 years old 2. ischemic wake up stroke (unknown time of onset but less than 24 hours since last seen normal) 3. national institute of health stroke scale (nihss) 8-22 4. evidence of penumbra on computed tomography perfusion(ctp) as mentioned above 5. alberta stroke program early computed tomography (ct) score (aspects 7 or more) 6. signed informed consent exclusion criteria: exclusion criteria: potential study patients will be excluded from study entry if any of the following exclusion criteria exist at the time of screening: 1. evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage (sah), epidural hemorrhage, acute or chronic subdural hematoma (sdh)) on the baseline ct 2. historical modified rankin scale (mrs) of ≥2 3. national institute of health stroke scale (nihss)\<8 at the time of treatment 4. positive pregnancy test in women at age of childbearing 5. intracranial or intraspinal surgery within 3 months 6. stroke or serious head injury within 3 months 7. history of intracranial hemorrhage 8. uncontrolled hypertension at time of treatment (eg, \>185 mm hg systolic or \>110 mm hg diastolic) 9. seizure at the onset of stroke 10. active internal bleeding 11. intracranial neoplasm 12. arteriovenous malformation or aneurysm 13. clinical presentation suggesting post-mi pericarditis 14. known bleeding diathesis including but not limited to current use of oral anticoagulants producing an internation normalized ratio (inr) \>1.7 15. internation normalized ratio (inr) \>1.7 16. administration of heparin within 48 hours preceding the onset of stroke with an elevated activated partial thromboplastin time(aptt) at presentation 17. platelet count \<100,000/mm 18. major surgery within 2 weeks 19. gastrointestinal (gi) or urinary tract hemorrhage within 3 weeks 20. aggressive treatment required to lower blood pressure 21. glucose level \ 400 mg/dl 22. arterial puncture at a noncompressible site or lumbar puncture within 1 week
involvement of the gut microbiota in calcified aortic stenosis

Conditions: Aortic Stenosis; Gastrointestinal Microbiome; Metabolomics

Summary: calcific aortic stenosis (cas) is a disease characterized by progressive calcification of the aortic valve, obstructing the passage of blood from the left ventricle into the general circulation. it is the most frequent cause of valve disease in the elderly. to date, no means of preventing the disease has been discovered, and the only treatment available is valve replacement during cardiac surgery, or percutaneous implantation of a valve prosthesis when the narrowing becomes severe and causes symptoms. the intestinal flora or microbiota, the reservoir of all the microorganisms in the gut, is implicated in numerous diseases, particularly of the intestine. but to date, no study has established a link between cas and microbiota. the intestinal microbiota acts through molecules produced by itself or the host and passing into the bloodstream. in the pathophysiology of cas, the valve leaflets are breached and do not heal. these molecules can enter and have beneficial or deleterious effects, in particular promoting calcification of aortic valve cells. concrete objectives: improve understanding of calcific aortic stenosis in humans study the composition of intestinal flora in patients with aortic stenosis and compare it with healthy subjects study the molecules in the intestinal flora likely to be involved in the development of aortic stenosis in humans.


Eligibility criteria:
inclusion criteria: * group of patients with cas: * calcified aortic stenosis diagnosed on a cardiac ultrasound or ct not older than 3 months * severe aortic stenosis: surgical indication based on symptoms and ultrasound data (high gradient aortic stenosis : vmax\> 4m/s, mean gradient \> 40mmhg, area \ 55%, vmax\< 4m/s, mean gradient \< 40mmhg, area \< 1cm²) * moderate cas: 3m/s \<vmax\< 4m/s, 20mmhg \< mean gradient \< 40mmhg * mild cas: 2,6m/s \< vmax \< 2.9m/s, mean gradient \< 20mmhg * aortic sclerosis: calcified remodeling of the aortic valve visible on ultrasound or ct. control group - free of cas: - no calcified aortic stenosis verified on a cardiac ultrasound or ct not older than 3 months exclusion criteria: * treatment interfering with the composition of the intestinal microbiota: local or systemic corticosteroids within the last 3 months, antibiotics within the last 3 months, antiretrovirals, bile acid chelators (questran and colesevelam), hiv-targeted antiretroviral therapies, selective serotonin reuptake inhibitor-type antidepressants * clinical criteria: history of cholecystectomy, documented chronic liver disease in the patient, failure to fast on the day of the blood test, inflammatory bowel disease * patients requiring emergency intervention (myocardial infarction, acute aortic or mitral insufficiency, cardiogenic shock). * as of rheumatic origin, infective endocarditis.